SAN FRANCISCO, April 27, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that...
Hence then, the article about ibrx shareholder update immunitybio ibrx sued after fda flags misleading cancer claims shares plunge 21 2b market cap lost hagens berman was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman )
Also on site :
- Hi3D V1.0 se vuelve de código abierto: el primer modelo 3D de IA de código abierto validado para producción
- 100 Years Ago Today, Harry Houdini Took the Stage With a 104-Degree Fever, and It Was the Last Show He Ever Performed
- Box Office: ‘Clayface’ Lands at No. 1 with $10.4 Million Debut, ‘You Can See Everything’ Adds $6.14 Million on Friday